Developer docs
API playgroundTry for free, no card

Search company profiles

Charley's Fund

Full company profile

uuid02lzsby

Namestring
Charley's Fund
Legal namestring
Charley's Fund, Inc.
Company typeenum
Private
Founded yearint
2004
Descriptiontext

Charley's Fund is a 501(c)(3) tax-exempt public charity founded in 2004 by Tracy and Benjamin Seckler after their son Charley was diagnosed with Duchenne muscular dystrophy at age three. The organization is headquartered in Great Barrington, Massachusetts, and operates with a lean staff of 1-10 employees, channeling 91 cents of every dollar spent directly to programmatic efforts. Over an 18-year history, the organization has directed more than $50 million to medical research, drug development, and the improvement of tools and resources in the DMD research and care ecosystem, and reports that 50+ DMD treatment programs are now in active development versus zero approximately 15 years prior.

The organization's core portfolio is anchored by The Duchenne Program at UMass Chan Medical School in Worcester, MA, launched in July 2018 with a $6 million, five-year commitment from Charley's Fund and operating as the first multidisciplinary DMD clinic in the Northeast, serving 400+ families directly with intensive two-day coordinated specialist visits and hosting multiple clinical trials. Supporting initiatives include the Of Mice and Measures (OMAM) program, a multi-institution effort launched in 2017 that standardized preclinical mouse-model protocols across 22+ institutions; support for the development of Electrical Impedance Myography (EIM) as a clinical trial outcome measure in partnership with Dr. Seward Rutkove; the Duchenne Video Assessments System developed with Casimir, a smartphone-based tool scored by trained physical therapists; and The Race to Yes advocacy movement, which engaged 100,000+ voices and contributed to the FDA's accelerated approval of Exondys 51 (eteplirsen), the first approved DMD therapy. The organization also participates in the international cTAP alliance.

Charley's Fund operates a donation-based revenue model, raising funds from individuals through preset donation tiers ($50, $250, $500, $1,000, and custom amounts), stock gifts, and community fundraising programs such as the annual Small Kids BIG Change youth initiative. Distribution is executed through co-funded grants to academic and clinical partners (e.g., Leiden University Medical Center, University of Bari, UMass Chan Medical School, Harvard/Beth Israel Deaconess) and through The Duchenne Program clinic. The customer/mission base is segmented into families of children and young adults with DMD (primary beneficiaries), DMD researchers and drug developers (grant and partnership recipients), and healthcare providers implementing coordinated DMD care models, with co-funding relationships maintained across a coalition of aligned family foundations including Duchenne UK, Ryan's Quest, Michael's Cause, Pietro's Fight, JB's Keys to DMD, Hope for Gus, the Nash Avery Foundation, Team Joseph, and Joining Jack.

Short descriptiontext

Charley's Fund is a 501(c)(3) nonprofit founded in 2004 that funds research, clinical programs, and advocacy to accelerate treatments for Duchenne muscular dystrophy, operating The Duchenne Program at UMass Chan Medical School and deploying $50M+ across 50+ active DMD treatment programs.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersGreat Barrington, United States
HQ citystring
Great Barrington
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
duchenne muscular dystrophy research, nonprofit medical foundation, rare disease advocacy, clinical care programs, preclinical drug development
Industry3 codes
PRIMARYBPAGACAA
Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS)
SECONDARYBPAGAKAL
Health & Medical Research Grantmaking Foundations
Business & Public Services/Nonprofit, NGO & Social Services/Philanthropy, Foundations & Grantmaking
SECONDARYBPADAOAB
Grantmaking & Philanthropic Funds (Institutional Donors)
Business & Public Services/International Organizations & Development/Donor Coordination, Grantmaking & Development Finance Programs
NAICS code2 codes
  • Voluntary Health Organizations813212
  • Grantmaking Foundations813211
SIC code2 codes
  • Services-Social Services8300
  • Services-Misc Health & Allied Services, Nec8090
Product category
Nonprofit medical research foundation — Duchenne muscular dystrophy
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Donations and Fundraising
TypeGrants Donations
Description

As a 501(c)(3) nonprofit public charity, Charley's Fund generates revenue primarily through individual donations. The organization runs annual fundraising campaigns including the 'Small Kids BIG Change' youth program with preset donation amounts ($50, $250, $500, $1000, and custom). The website also mentions stock donations as an option.

charleysfund.org
Marketing channels10 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Others, Marketing or Sales, Operations
Pricing details1 tier
1Donation-based revenue model with preset and custom amounts
ModelOtherBilling cadenceOne time/ perpetual license
Notes

Preset donation amounts: $50, $250, $500, $1000, plus custom options. Stock donations also accepted via phone (413-528-0400).

charleysfund.org
GTM typeB2B and B2C
B2B and B2C
Offering typeServices
Services
Core offering1 text field

Charley's Fund is a 501(c)(3) nonprofit public charity that funds medical research, drug development, clinical programs, and advocacy to accelerate treatments for Duchenne muscular dystrophy. The organization channels individual donations and collaborative grants into preclinical research standardization, novel clinical outcome measures, and The Duchenne Program at UMass Chan Medical School — a multidisciplinary clinic that delivers coordinated care to 400+ families while hosting clinical trials. Complementary initiatives include regulatory advocacy (The Race to Yes) and community engagement programs that mobilize donor and family support.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • $50 million+ deployed to Duchenne research and care ecosystem over 18 years
+4 more records
Product overview1 text field

Charley's Fund is a nonprofit organization (501(c)(3)) founded in 2004 by Tracy and Benjamin Seckler after their son Charley was diagnosed with Duchenne muscular dystrophy. The organization does not offer a traditional product but rather operates a portfolio of interconnected programs and initiatives to accelerate Duchenne treatments. The flagship initiative is The Duchenne Program at UMass Chan Medical School, a world-class multidisciplinary clinic serving 400+ families. Supporting programs include Of Mice and Measures (improving preclinical research models), Electrical Impedance Myography and Duchenne Video Assessments (novel outcome measures for clinical trials), and The Race to Yes (regulatory advocacy). The organization has deployed over $50 million to advance therapeutic development for Duchenne.

Product and service1 record
1The Duchenne Program at UMass Chan Medical School
CategoryMultidisciplinary clinical care for Duchenne muscular dystrophy
Description

A world-class multidisciplinary medical clinic exclusively dedicated to Duchenne muscular dystrophy and Becker muscular dystrophy, located at UMass Memorial's ambulatory care center in Worcester, MA. The clinic provides comprehensive, coordinated care to 400+ families from infants to adults, integrates clinical trials, and advances therapeutic development through research. Families attend intensive two-day visits (Wednesdays and Thursdays) for integrated specialist appointments.

Scale indicator14 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2018-07-01
Description

Multi-year partnership to establish The Duchenne Program, a world-class multidisciplinary clinic at UMass Medical School in Worcester, MA. The clinic is exclusively dedicated to Duchenne care and research, serving 400+ families directly. Charley's Fund committed $6 million over five years. The program provides integrated, coordinated care while advancing clinical trials.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Michigan-based partner in The Race to Yes initiative, working together to advocate for faster FDA regulatory processes for Duchenne treatments. This partnership successfully influenced accelerated approval of Exondys 51.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Academic research partners conducting the Of Mice and Measures preclinical study, evaluating best practices for D2/mdx and BL10/mdx mouse models.

4University of Bari (Prof. Annamaria De Luca)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Academic research partner conducting the Of Mice and Measures preclinical study alongside Leiden University.

charleysfund.org
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Company developing the Duchenne Video Assessments System. Co-founded by two parents of boys with DMD. Charley's Fund supports their clinical study to test the scoring scale's reliability.

6Dr. Seward Rutkove (Harvard/Beth Israel Deaconess)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

EIM pioneer whose work Charley's Fund has supported to evaluate Electrical Impedance Myography as an outcome measure for Duchenne clinical trials.

charleysfund.org
Strategic tierCoreTypeStrategic or Co-development Partner
Description

International alliance of Duchenne companies, physicians, nonprofits, and statistical experts working to pool resources and identify solutions to drug development problems. Charley's Fund President and COO Laura Dalle Pazze serves as an active participant.

8Dr. Brenda Wong
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Founding clinic director of The Duchenne Program at UMass. Brought from Cincinnati where she directed the Comprehensive Neuromuscular Center for 19 years.

charleysfund.org
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1Casimir
TypeEmerging player
Description

Company developing the Duchenne Video Assessments System, co-founded by parents of boys with DMD. Charley's Fund supports Casimir's clinical study, making it a directly comparable patient-driven DMD research collaboration.

TypeDirect peer
Description

UK-based DMD-focused nonprofit that co-funds preclinical research with Charley's Fund (e.g., the $314K Leiden/Bari grant). Directly comparable disease focus, research funding model, and patient advocacy activities.

TypeDirect peer
Description

Family-founded DMD nonprofit providing patient programming, advocacy, and research funding. Comparable donor base (DMD families) and patient-services-plus-research hybrid model.

TypeDirect peer
Description

The largest U.S. nonprofit focused exclusively on Duchenne and Becker muscular dystrophy. Directly comparable mission (DMD research funding, advocacy, patient programs) and donor base; Charley's Fund operates in the same niche with overlapping partnerships (e.g., cTAP).

TypeBroad incumbent
Description

Long-established, broad-scope neuromuscular disease nonprofit that funds DMD research and runs multidisciplinary clinics. Comparable care-delivery and grantmaking model but covers all neuromuscular diseases rather than focusing exclusively on Duchenne.

TypeDirect peer
Description

U.S. DMD-focused nonprofit funding drug development and clinical research. Comparable grantmaking model targeting translational DMD research, with overlapping biotech and academic partners.

TypeEmerging player
Description

International alliance of DMD companies, physicians, nonprofits, and statisticians pooling data to address drug-development challenges. Charley's Fund President Laura Dalle Pazze is an active participant; comparable mission focus on accelerating DMD trial design.

8Casimir (alternative: NIH National Institute of Neurological Disorders and Stroke)
TypeBroad incumbent
Description

Public-sector funder of large-scale DMD research grants and outcome-measure development (e.g., supporting EIM and similar biomarker work). Comparable research-grantmaking activity but with vastly larger budget and broader neurological scope.

9Joining Jack
TypeDirect peer
Description

UK-based DMD nonprofit that co-funded neutrophil elastase inhibitor research with Charley's Fund. Directly comparable disease focus and translational research funding approach.

TypeDirect peer
Description

Family-founded DMD nonprofit co-funding preclinical studies alongside Charley's Fund, Duchenne UK, Michael's Cause, and Pietro's Fight. Directly comparable funding model and mission focus.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Charley's Fund

Nonprofit medical research foundation — Duchenne muscular dystrophycharleysfund.org

Charley's Fund is a 501(c)(3) nonprofit founded in 2004 that funds research, clinical programs, and advocacy to accelerate treatments for Duchenne muscular dystrophy, operating The Duchenne Program at UMass Chan Medical School and deploying $50M+ across 50+ active DMD treatment programs.

What Charley's Fund does

Charley's Fund is a 501(c)(3) tax-exempt public charity founded in 2004 by Tracy and Benjamin Seckler after their son Charley was diagnosed with Duchenne muscular dystrophy at age three. The organization is headquartered in Great Barrington, Massachusetts, and operates with a lean staff of 1-10 employees, channeling 91 cents of every dollar spent directly to programmatic efforts. Over an 18-year history, the organization has directed more than $50 million to medical research, drug development, and the improvement of tools and resources in the DMD research and care ecosystem, and reports that 50+ DMD treatment programs are now in active development versus zero approximately 15 years prior.

The organization's core portfolio is anchored by The Duchenne Program at UMass Chan Medical School in Worcester, MA, launched in July 2018 with a $6 million, five-year commitment from Charley's Fund and operating as the first multidisciplinary DMD clinic in the Northeast, serving 400+ families directly with intensive two-day coordinated specialist visits and hosting multiple clinical trials. Supporting initiatives include the Of Mice and Measures (OMAM) program, a multi-institution effort launched in 2017 that standardized preclinical mouse-model protocols across 22+ institutions; support for the development of Electrical Impedance Myography (EIM) as a clinical trial outcome measure in partnership with Dr. Seward Rutkove; the Duchenne Video Assessments System developed with Casimir, a smartphone-based tool scored by trained physical therapists; and The Race to Yes advocacy movement, which engaged 100,000+ voices and contributed to the FDA's accelerated approval of Exondys 51 (eteplirsen), the first approved DMD therapy. The organization also participates in the international cTAP alliance.

Charley's Fund operates a donation-based revenue model, raising funds from individuals through preset donation tiers ($50, $250, $500, $1,000, and custom amounts), stock gifts, and community fundraising programs such as the annual Small Kids BIG Change youth initiative. Distribution is executed through co-funded grants to academic and clinical partners (e.g., Leiden University Medical Center, University of Bari, UMass Chan Medical School, Harvard/Beth Israel Deaconess) and through The Duchenne Program clinic. The customer/mission base is segmented into families of children and young adults with DMD (primary beneficiaries), DMD researchers and drug developers (grant and partnership recipients), and healthcare providers implementing coordinated DMD care models, with co-funding relationships maintained across a coalition of aligned family foundations including Duchenne UK, Ryan's Quest, Michael's Cause, Pietro's Fight, JB's Keys to DMD, Hope for Gus, the Nash Avery Foundation, Team Joseph, and Joining Jack.

Charley's Fund firmographics

Firmographics
Name
Charley's Fund
Legal name
Charley's Fund, Inc.
Website
https://charleysfund.org
Company type
Private
Founded year
2004
Operating status
Operating
Headcount range
1–10 employees
Short description
Charley's Fund is a 501(c)(3) nonprofit founded in 2004 that funds research, clinical programs, and advocacy to accelerate treatments for Duchenne muscular dystrophy, operating The Duchenne Program at UMass Chan Medical School and deploying $50M+ across 50+ active DMD treatment programs.
Ownership category
akta.pro rank

Charley's Fund industry classification

Industry
Product category
Nonprofit medical research foundation — Duchenne muscular dystrophy
NAICS
Voluntary Health Organizations (813212), Grantmaking Foundations (813211)
SIC
Services-Social Services (8300), Services-Misc Health & Allied Services, Nec (8090)
akta.pro industry
PRIMARYBPAGACAA
Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS)
SECONDARYBPAGAKAL
Health & Medical Research Grantmaking Foundations
Business & Public Services/Nonprofit, NGO & Social Services/Philanthropy, Foundations & Grantmaking
SECONDARYBPADAOAB
Grantmaking & Philanthropic Funds (Institutional Donors)
Business & Public Services/International Organizations & Development/Donor Coordination, Grantmaking & Development Finance Programs

Keywords

  • Duchenne muscular dystrophy research
  • Nonprofit medical foundation
  • Rare disease advocacy
  • Clinical care programs
  • Preclinical drug development

Where Charley's Fund is headquartered

Location

Headquarters

HQ city
Great Barrington
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Charley's Fund business model

Business model
GTM type
B2B and B2C
Offering type
Services
Cost components
Personnel, Others, Marketing or Sales, Operations

Revenue model

  1. Donations and Fundraising: As a 501(c)(3) nonprofit public charity, Charley's Fund generates revenue primarily through individual donations. The organization runs annual fundraising campaigns including the 'Small Kids BIG Change' youth program with preset donation amounts ($50, $250, $500, $1000, and custom). The website also mentions stock donations as an option.

Pricing tiers

ModelBillingPrice
OtherOne time/ perpetual licenseDonation-based revenue model with preset and custom amounts

Go-to-market motion2 records

Distribution channels1 record

Marketing channels10 records

Charley's Fund product offering

Product offering

Core offering

Charley's Fund is a 501(c)(3) nonprofit public charity that funds medical research, drug development, clinical programs, and advocacy to accelerate treatments for Duchenne muscular dystrophy. The organization channels individual donations and collaborative grants into preclinical research standardization, novel clinical outcome measures, and The Duchenne Program at UMass Chan Medical School — a multidisciplinary clinic that delivers coordinated care to 400+ families while hosting clinical trials. Complementary initiatives include regulatory advocacy (The Race to Yes) and community engagement programs that mobilize donor and family support.

Product overview

Charley's Fund is a nonprofit organization (501(c)(3)) founded in 2004 by Tracy and Benjamin Seckler after their son Charley was diagnosed with Duchenne muscular dystrophy. The organization does not offer a traditional product but rather operates a portfolio of interconnected programs and initiatives to accelerate Duchenne treatments. The flagship initiative is The Duchenne Program at UMass Chan Medical School, a world-class multidisciplinary clinic serving 400+ families. Supporting programs include Of Mice and Measures (improving preclinical research models), Electrical Impedance Myography and Duchenne Video Assessments (novel outcome measures for clinical trials), and The Race to Yes (regulatory advocacy). The organization has deployed over $50 million to advance therapeutic development for Duchenne.

Differentiator

Problem solved

Functional benefit

Products and services

  • The Duchenne Program at UMass Chan Medical School A world-class multidisciplinary medical clinic exclusively dedicated to Duchenne muscular dystrophy and Becker muscular dystrophy, located at UMass Memorial's ambulatory care center in Worcester, MA. The clinic provides comprehensive, coordinated care to 400+ families from infants to adults, integrates clinical trials, and advances therapeutic development through research. Families attend intensive two-day visits (Wednesdays and Thursdays) for integrated specialist appointments.

Quantifiable outcome

  • $50 million+ deployed to Duchenne research and care ecosystem over 18 years
  • +4 more outcomes

Companies that use Charley's Fund

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles4 records

Charley's Fund technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Charley's Fund partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered core.

  • UMass Chan Medical School / The Duchenne ProgramcoreStrategic or Co-development Partner · 1 July 2018Multi-year partnership to establish The Duchenne Program, a world-class multidisciplinary clinic at UMass Medical School in Worcester, MA. The clinic is exclusively dedicated to Duchenne care and research, serving 400+ families directly. Charley's Fund committed $6 million over five years. The program provides integrated, coordinated care while advancing clinical trials.
  • Team JosephcoreStrategic or Co-development PartnerMichigan-based partner in The Race to Yes initiative, working together to advocate for faster FDA regulatory processes for Duchenne treatments. This partnership successfully influenced accelerated approval of Exondys 51.
  • Leiden University Medical Center (Prof. Annemieke Aartsma-Rus and Dr. Maaike van Putten)coreStrategic or Co-development PartnerAcademic research partners conducting the Of Mice and Measures preclinical study, evaluating best practices for D2/mdx and BL10/mdx mouse models.
  • University of Bari (Prof. Annamaria De Luca)coreStrategic or Co-development PartnerAcademic research partner conducting the Of Mice and Measures preclinical study alongside Leiden University.
  • CasimircoreStrategic or Co-development PartnerCompany developing the Duchenne Video Assessments System. Co-founded by two parents of boys with DMD. Charley's Fund supports their clinical study to test the scoring scale's reliability.
  • Dr. Seward Rutkove (Harvard/Beth Israel Deaconess)coreStrategic or Co-development PartnerEIM pioneer whose work Charley's Fund has supported to evaluate Electrical Impedance Myography as an outcome measure for Duchenne clinical trials.
  • cTAP (Collaborative Trajectory Analysis Project)coreStrategic or Co-development PartnerInternational alliance of Duchenne companies, physicians, nonprofits, and statistical experts working to pool resources and identify solutions to drug development problems. Charley's Fund President and COO Laura Dalle Pazze serves as an active participant.
  • Dr. Brenda WongcoreStrategic or Co-development PartnerFounding clinic director of The Duchenne Program at UMass. Brought from Cincinnati where she directed the Comprehensive Neuromuscular Center for 19 years.

Scale indicators14 records

Recent moves6 records

Expansion highlights5 records

Charley's Fund competitors and assessment

Company assessment

Emerging players

  • Casimir: Company developing the Duchenne Video Assessments System, co-founded by parents of boys with DMD. Charley's Fund supports Casimir's clinical study, making it a directly comparable patient-driven DMD research collaboration.
  • cTAP (Collaborative Trajectory Analysis Project): International alliance of DMD companies, physicians, nonprofits, and statisticians pooling data to address drug-development challenges. Charley's Fund President Laura Dalle Pazze is an active participant; comparable mission focus on accelerating DMD trial design.

Direct peers

  • Duchenne UK: UK-based DMD-focused nonprofit that co-funds preclinical research with Charley's Fund (e.g., the $314K Leiden/Bari grant). Directly comparable disease focus, research funding model, and patient advocacy activities.
  • Jett Foundation: Family-founded DMD nonprofit providing patient programming, advocacy, and research funding. Comparable donor base (DMD families) and patient-services-plus-research hybrid model.
  • Parent Project Muscular Dystrophy (PPMD): The largest U.S. nonprofit focused exclusively on Duchenne and Becker muscular dystrophy. Directly comparable mission (DMD research funding, advocacy, patient programs) and donor base; Charley's Fund operates in the same niche with overlapping partnerships (e.g., cTAP).
  • Cure Duchenne: U.S. DMD-focused nonprofit funding drug development and clinical research. Comparable grantmaking model targeting translational DMD research, with overlapping biotech and academic partners.
  • Joining Jack: UK-based DMD nonprofit that co-funded neutrophil elastase inhibitor research with Charley's Fund. Directly comparable disease focus and translational research funding approach.
  • Ryan's Quest: Family-founded DMD nonprofit co-funding preclinical studies alongside Charley's Fund, Duchenne UK, Michael's Cause, and Pietro's Fight. Directly comparable funding model and mission focus.

Broad incumbents

  • Muscular Dystrophy Association (MDA): Long-established, broad-scope neuromuscular disease nonprofit that funds DMD research and runs multidisciplinary clinics. Comparable care-delivery and grantmaking model but covers all neuromuscular diseases rather than focusing exclusively on Duchenne.
  • Casimir (alternative: NIH National Institute of Neurological Disorders and Stroke): Public-sector funder of large-scale DMD research grants and outcome-measure development (e.g., supporting EIM and similar biomarker work). Comparable research-grantmaking activity but with vastly larger budget and broader neurological scope.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Charley's Fund social profiles

Digital presence

Charley's Fund financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Charley's Fund leadership team

Management profile

Number of profiles

Profiles3 records

Charley's Fund funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Charley's Fund M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Charley's Fund

What does Charley's Fund do?

Charley's Fund is a 501(c)(3) nonprofit public charity that funds medical research, drug development, clinical programs, and advocacy to accelerate treatments for Duchenne muscular dystrophy. The organization channels individual donations and collaborative grants into preclinical research standardization, novel clinical outcome measures, and The Duchenne Program at UMass Chan Medical School — a multidisciplinary clinic that delivers coordinated care to 400+ families while hosting clinical trials. Complementary initiatives include regulatory advocacy (The Race to Yes) and community engagement programs that mobilize donor and family support.

Is Charley's Fund a public or private company?

Charley's Fund is a private company. It is classified as nonprofit foundation owned and is currently operating.

When was Charley's Fund founded?

Charley's Fund was founded in 2004. It employs 1 to 10 people.

Where is Charley's Fund based?

Charley's Fund is headquartered in Great Barrington, United States, in the North America region.

How does Charley's Fund make money?

One revenue line is on record: donations and Fundraising.

Who are Charley's Fund's main competitors?

Emerging players on record are Casimir and cTAP (Collaborative Trajectory Analysis Project). Direct peers are Duchenne UK, Jett Foundation, Parent Project Muscular Dystrophy (PPMD), Cure Duchenne, Joining Jack and Ryan's Quest. Broad incumbents are Muscular Dystrophy Association (MDA) and Casimir (alternative: NIH National Institute of Neurological Disorders and Stroke).

Does Charley's Fund have an API?

No public API is recorded for Charley's Fund.

What industry is Charley's Fund in?

Charley's Fund's product category is Nonprofit medical research foundation — Duchenne muscular dystrophy. Its primary akta.pro industry code is BPAGACAA, Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS), with a secondary code of BPAGAKAL, Health & Medical Research Grantmaking Foundations. Its NAICS code is 813212 and its SIC code is 8300.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales